AHCC RESEARCH  Manufacturer Contact Us |
|
Press Release American Cancer Patients Turn To Japanese Mushrooms Medicinal Mushroom also Helps those with AIDs, Hepatitis and Diseases Rye, New York, April 13, 2001 - Many American cancer patients are now turning to Japanese medicinal mushrooms to improve their quality of life. Taken as a nutritional supplement to boost the immune system, Active Hexose Correlated Compound (AHCC) is finding its way to the U.S. after 14 years of extensive use in Japanese hospitals and medical clinics. "AHCC is increasingly being used in my clinical practice and many others as an efficacious nutritional supplement for those with cancer, hepatitis, and other ailments involving immune dysfunction," said Fred Pescatore, M.D., M.P.H., of the Centers For Integrative and Complementary Medicine, and medical director for the AHCC Research Association. "The many clinical studies performed in Japan on this supplement indicate that it increases critical immune parameters such as Natural Killer Cells, Killer T-Cells and macrophages. When this happens, a patient's immune system improves and a higher quality of life is achieved." AHCC is derived from a highly specialized manufacturing process developed in the mid-1980s that relies on the hybridization of several species of mushrooms cultivated in Japan. AHCC In U.S. According to industry analysts in Japan, currently over 700 hospitals and medical clinics recommend AHCC to patients in that country as part of an immune support regimen. This has led to 35,000 individuals worldwide using the nutritional supplement with American cancer patients just now starting to realize AHCC's benefits. "I was diagnosed with prostrate cancer in 1995 and was told that I had only two more years to live," said 60 year-old Ted Taylor of Carmichael, CA. "Following chemotherapy, my physician recommended AHCC as a way to make my immune system stronger. Since then I've taken AHCC every day. I have hardly been ill. My energy levels seem to be up, and my overall wellness is better than before the cancer." In the 14 years since AHCC's introduction to the market, it has been the subject of hundreds of clinical studies, most of which have been conducted in Japan. However, several studies are slated for 2001 in the U.S. at institutions such as Harvard and the University of California, Davis. Additionally, the recent formation of the AHCC Research Association will serve as a catalyst to encourage more studies in North America, as well as patient education about the benefits of the nutritional supplement.
|